Xuan Y, Sheng Y, Zhang D, et al. Targeting CD276 by CAR-T Cells Induces Regression of Esophagus Squamous Cell Carcinoma in Xenograft Mouse Models. Translational Oncology. 2021; 14 (8): 101138 (doi: 10.1016/j.tranon.2021.101138).
Chimeric antigen receptor (CAR) T cell therapy targeting CD276 is a promising treatment pathway for esophageal squamous cell carcinoma (ESCC), researchers report. The immune checkpoint molecule is aggressively and homogenously overexpressed in ESCC tumor lesions, but its expression in healthy tissues is mild. In patient-derived xenograft models — which extract human tumor tissues and transplant them to mice in order to explore treatment viability — CAR T cells directed at CD276 exhibited robust anti-tumor activity, promoted tumor regression, and prolonged mouse survival. Investigators also demonstrated that CD276-targeting CAR T cells can be successfully generated from patient T cells and they then deliver powerful cytotoxicity against autologous tumor cells. Based on the evidence, the study authors believe clinical trials evaluating CD276-targeting CAR T cells as a treatment for ESCC are warranted.
Tags: astct, Treatment, T-cells, CAR T, Abstracts, Science, translational, newsletter, CD276, CAR T-cells, ESCC